Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
34.73
-1.05 (-2.93%)
Aug 11, 2026, 11:43 AM EDT - Market open
Roivant Sciences Cash Flow Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -414.6 | -397.91 | -356.73 | 4,231 | -1,115 | -924.12 |
Depreciation & Amortization | 2.85 | 3.35 | 14.07 | 22.04 | 18.86 | 5.93 |
Stock-Based Compensation | 347.33 | 346.17 | 289.03 | 199.63 | 217.78 | 564.96 |
Other Adjustments | -137.43 | -80.16 | -708.77 | -5,237 | 29.09 | -340.22 |
Changes in Accounts Payable | 22.27 | 3.42 | -18.17 | 22.68 | 4.36 | 15.4 |
Changes in Accrued Expenses | 70.42 | 59.33 | -10.07 | 62.13 | 57.53 | 50.6 |
Changes in Income Taxes Payable | 77.86 | 85.05 | -10.05 | 9.93 | - | - |
Changes in Other Operating Activities | -779.58 | -769.59 | -38.76 | -75.7 | -55.54 | -50.28 |
Operating Cash Flow | -816.47 | -750.35 | -839.45 | -765.27 | -843.39 | -677.73 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -4.59 | -8.21 | -4.6 | -1.38 | -12.69 | -17.44 |
Purchases of Investments | -502.27 | -4,796 | -4,062 | - | - | - |
Proceeds from Sale of Investments | 3,155 | 4,129 | 1,960 | - | 114.56 | 320.17 |
Proceeds from Business Divestments | - | - | 370.97 | 5,281 | - | - |
Other Investing Activities | - | -6.94 | -31.14 | -75.89 | -146.14 | 0.56 |
Investing Cash Flow | 684.64 | -682.33 | -1,766 | 5,204 | -44.27 | 303.3 |
Long-Term Debt Issued | - | - | - | - | 159.9 | 36.4 |
Long-Term Debt Repaid | - | - | -52.75 | -30.71 | -30.14 | -21.59 |
Net Long-Term Debt Issued (Repaid) | - | - | -52.75 | -30.71 | 129.76 | 14.81 |
Issuance of Common Stock | 316.1 | 269.51 | 50.63 | 255.09 | 315.11 | 313.84 |
Repurchase of Common Stock | -407.06 | -366.72 | -1,330 | -37.76 | -10.88 | - |
Net Common Stock Issued (Repurchased) | -90.96 | -97.22 | -1,280 | 217.34 | 304.23 | 313.84 |
Other Financing Activities | - | 231.46 | 112.78 | 232.73 | 65.48 | -21.85 |
Financing Cash Flow | 140.49 | 134.24 | -1,220 | 419.36 | 499.46 | 306.79 |
Foreign Exchange Rate Adjustments | 3.27 | 3.77 | 0.75 | 0.62 | 6.28 | - |
Net Cash Flow | 11.93 | -1,295 | -3,825 | 4,858 | -381.92 | -67.64 |
Free Cash Flow | -821.06 | -758.56 | -844.05 | -766.65 | -856.08 | -695.17 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -10901.00% | -9183.51% | -2905.21% | -2343.56% | -1397.00% | -1257.40% |
Free Cash Flow Per Share | -1.13 | -1.09 | -1.16 | -0.92 | -1.20 | -1.04 |
Levered Free Cash Flow | -877.02 | -926.43 | -292.31 | 4,358 | -866.76 | -826.24 |
Unlevered Free Cash Flow | -1,463 | -1,401 | -1,142 | 4,516 | -1,168 | -1,348 |